** Shares of Celltrion 068270.KS , South Korea's top
biopharma firm, fall more than 7 pct, after Ion Investments,
which is controlled by Temasek Holdings of Singapore, sells part
of the co's stake on Monday
** The block deal, worth of $793 million, was made after
market close on Monday, and 3.625 million shares were sold by
Tamesek Holdings, according to Credit Suisse which conducted the
transaction
** Each share was traded at 247,000 won ($217.46), down 8
pct from Monday's closing price of 268,500 won, and buyers
included global hedge funds and local institutions, the
investment bank added
** The block deal was oversubscribed, it said
** In March, Ion Investment sold up to 2,240,000 shares of
Celltrion, and the pricing represented a discount of 6 to 9 pct
to their pre-deal close urn:newsml:reuters.com:*:nL4N1QO3TD
** Other medical shares drop over the deal, says Kim
Tae-hee, analyst at Mirae Asset Daewoo. Samsung Biologics
207940.KS and Hanmi Pharm 128940.KS fall 4 pct and 2.7 pct,
respectively, while the medical sub-index .KS32 is down 4.4
pct
** The broader KOSPI market .KS11 was trading down 1.5 pct
as of 0103 GMT
($1 = 1,135.8400 won)
((hayoung.choi.thomsonreuters.com@reuters.net
yena.park.thomsonreuters.com@reuters.net))